-+ 0.00%
-+ 0.00%
-+ 0.00%
Sumitomo Seika Chemicals (TSE:4008) Stock Faces Valuation Questions After Profit Rebound
Share
Listen to the news

Sumitomo Seika Chemicals came into this earnings print with the stock on a strong run, up around 20% over the past month and pricing in a cleaner story after a tough few years. The immediate question for you now is whether the latest quarter justifies that confidence or stretches it.

The headline is clear. Q1 2027 delivered earnings per share of ¥50.52 on revenue of ¥40,397m, with trailing year earnings up sharply and net margin sitting at 6.5%. At a P/E of 10.1x and a 3.11% dividend yield, the market is weighing that profit strength against a valuation that already assumes a lot has been fixed.

Is Sumitomo Seika Chemicals Company trading at a sensible price for this rebound in earnings, or has sentiment already run too far ahead of fundamentals? Compare its current multiples and cash flow assumptions inside the valuation analysis for Sumitomo Seika Chemicals Company

Q1 2027 Earnings Summary

  • Revenue (Q1 2027 vs Q1 2026): ¥40,397m vs. ¥35,569m (up approximately 13.6%)
  • Net Income (Excl. Extra Items, Q1 2027 vs Q1 2026): ¥3,263m vs. ¥1,045m (up approximately 212.2%)
  • Basic EPS (Q1 2027 vs Q1 2026): ¥50.52 vs. ¥15.95 (up approximately 216.9%)
  • Net Profit Margin (Trailing 12 Months vs Prior Year): 6.5% vs. 3.1% (margin roughly doubled, indicating stronger profitability for Sumitomo Seika Chemicals)

Prefer clean charts to another wall of earnings tables and ratios? See Sumitomo Seika Chemicals Company’s full financial picture with an at a glance view of its valuation in the visual company report for Sumitomo Seika Chemicals Company.

TSE:4008 Trailing 12-Month Earnings & Revenue History as at Aug 2026
TSE:4008 Trailing 12-Month Earnings & Revenue History as at Aug 2026

Stronger earnings back the defensive Sumitomo Seika story

The latest quarter gives supporters of Sumitomo Seika Chemicals some clear evidence. Revenue of ¥40,397m and net income of ¥3,263m both move in the same positive direction against Q1 2026. Earnings per share more than tripled, which fits the idea of a specialized chemicals business with improving profitability rather than a plain commodity producer. A trailing net margin of 6.5% compared with 3.1% a year earlier also supports the view that exposure to hygiene and healthcare related end markets can translate into a healthier earnings profile.

Risks around cyclicality and sentiment still matter

Even with these stronger numbers, the cautious side of the Sumitomo Seika Chemicals story does not disappear. The business still operates across several segments, which can make it harder for you to judge how stable each profit stream is. The share price has risen roughly 20% over 30 days and about 28% over 90 days, so some of the good news is already reflected in recent returns. If margins or demand ease from here, the recent optimism could moderate quickly.

Review how Sumitomo Seika Chemicals has handled a long term earnings decline, and see whether other structural issues are quietly building in our risk analysis for Sumitomo Seika Chemicals Company which shows 1 important warning sign.

Take Control of Your Next Move

If the recent earnings rebound and margin improvement at Sumitomo Seika Chemicals Company has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and wait for a setup that fits your plan. After you own it, use the Portfolio Command Center to keep on top of essential alerts while cutting out day to day noise. For a broader view on what other investors are seeing in Sumitomo Seika Chemicals Company and similar stocks, join the conversation in the Community. This combination may help you identify potential catalysts and risks earlier so you can stay a step ahead of the market.

Seeking Alternatives Beyond Sumitomo Seika Chemicals?

Fresh stock ideas can move from under the radar to flying fast once momentum catches on. Scan these curations before the crowd catches up and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending